Please login to the form below

Not currently logged in
Email:
Password:

MHRA and Swissmedic pledge greater collaboration

Product safety regulators to share information and promote international cooperation
From left: Swissmedic's Jürg Schnetzer and MHRA's Dr Ian Hudson

From left: Swissmedic's Jürg Schnetzer and MHRA's Dr Ian Hudson

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and its Swiss counterpart Swissmedic have pledged to improve international collaboration in addressing product safety concerns.

The two regulatory agencies signed a memorandum of understanding at the Summit of the Heads of Medicines Regulatory Agencies, hosted by Swissmedic in Interlaken, Switzerland earlier this week.

Agreeing to support each other's regulatory frameworks, requirements and processes as well as share information - the topic of this year's summit - the two bodies look to lead the way in creating a more collaborative approach to international public health.

As part of the deal, the MHRA and Swissmedic will unite in combatting safety challenges in medicines, medical devices, and components for transfusion, such as the globalisation of therapeutic products research and production, and the increasing complexity of scientific and technological developments.

MHRA chief executive Dr Ian Hudson, commented: “Part of our commitment to protecting the health of UK citizens is by creating close ties with international counterparts.

“Through closer collaboration, we can provide a basis for increasing shared initiatives as well as create a foundation for easier information-sharing.

“We operate in a global environment and agreements such as these serve to further strengthen our ability to promote good practices and we look forward to working even closer with our Swiss counterparts.”

Article by
Rebecca Clifford

12th October 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics